Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financi...(A. The information in our website is not...)
| HOME >> BIOLOGY >> TECHNOLOGY |
A>. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.
KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com
Keryx Biopharmaceuticals, Inc.
Selected Consolidated Financial Data
(Thousands of Dollars, Except Share and Per Share Data)
Statements of Operations Information:
Three Months Ended March 31,
(unaudited)
2008 2007
REVENUE:
License revenue $199 $ --
Diagnostic revenue -- 30
Service revenue -- 12
TOTAL REVENUE 199 42
OPERATING EXPENSES:
Cost of diagnostics sold -- 22
Cost of services -- 32
Research and development:
Non-cash compensation (980) 995
Other research and development 30,828 17,446
Total research and development 29,848 18,441
Selling, general and administrative:
Non-cash compensation 1,717 2,006
Other selling, general and administrative 1,967 2,795
Total selling, general and administrative 3,684 4,801
TOTAL OPERATING EXPENSES 33,532 23,296
OPERATING LOSS
'/>"/>
| SOURCE Keryx Biopharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |